SymBio Pharmaceuticals Limited Logo

SymBio Pharmaceuticals Limited

Acquires and commercializes specialty drugs for unmet needs in Japan and the Asia-Pacific region.

4582 | T

Overview

Corporate Details

ISIN(s):
JP3383050006
LEI:
Country:
Japan
Address:
港区虎ノ門四丁目1番28号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

SymBio Pharmaceuticals Limited is a specialty pharmaceutical company dedicated to addressing unmet medical needs. Its core business model involves acquiring the rights to develop and commercialize promising new drug candidates from global bio-ventures and pharmaceutical firms. The company focuses on therapeutic areas including oncology, hematology, autoimmune diseases, and infectious diseases. SymBio aims to deliver innovative treatments to patients, particularly for conditions underserved by the broader industry, with a primary market focus on Japan and the Asia-Pacific region.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-05 02:11
Registration Form
確認書
Japanese 9.0 KB
2025-08-04 09:05
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 281.2 KB
2025-08-04 09:04
Interim Report
半期報告書-第21期(2025/01/01-2025/12/31)
Japanese 356.9 KB
2025-07-31 08:37
Registration Form
訂正有価証券届出書(参照方式)
Japanese 276.5 KB
2025-07-22 09:24
Registration Form
有価証券届出書(参照方式)
Japanese 524.8 KB
2025-04-21 03:23
Share Issue/Capital Change
訂正臨時報告書
Japanese 36.1 KB
2025-04-18 09:38
Share Issue/Capital Change
訂正臨時報告書
Japanese 40.4 KB
2025-03-26 05:29
Registration Form
訂正有価証券届出書(参照方式)
Japanese 207.2 KB
2025-03-26 05:04
Post-Annual General Meeting Information
臨時報告書
Japanese 26.2 KB
2025-03-25 07:35
Share Issue/Capital Change
臨時報告書
Japanese 44.1 KB
2025-03-25 07:34
Registration Form
訂正有価証券届出書(参照方式)
Japanese 312.0 KB
2025-03-25 07:32
Governance Information
内部統制報告書-第20期(2024/01/01-2024/12/31)
Japanese 23.9 KB
2025-03-25 07:31
Registration Form
確認書
Japanese 9.0 KB
2025-03-25 07:30
Annual Report
有価証券報告書-第20期(2024/01/01-2024/12/31)
Japanese 1.9 MB
2025-02-20 08:20
Registration Form
訂正有価証券届出書(参照方式)
Japanese 241.9 KB

Automate Your Workflow. Get a real-time feed of all SymBio Pharmaceuticals Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SymBio Pharmaceuticals Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SymBio Pharmaceuticals Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Solid Biosciences Inc. Logo
Advancing gene therapies and technologies for rare neuromuscular and cardiac diseases.
United States of America
SLDB
SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America
SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America
SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America
SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria
SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
SPRUCE BIOSCIENCES, INC. Logo
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB

Talk to a Data Expert

Have a question? We'll get back to you promptly.